Clinical Trial Update: Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF [Phase 1, Phase 2]

View source ↗

Summary

Clinical study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of POL6014 in cystic fibrosis patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• POL6014

Snippet

Sponsor: Santhera Pharmaceuticals | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED